Silence Therapeutics Aktiengesellschaft (Ag)

Calculating rank

USPTO Granted Patents = 5

% Expired Patents = 40.0

Forward Citations = 321

Loading Chart...

3 inventors (with patents filed for the assignee):

Jörg Kaufmann (5 out of 33 patents)

Anke Klippel-Giese (5 out of 17 patents)

Klaus Giese (4 out of 28 patents)

5 patents: Sort by Forward Citations

1. 8933215 - Interfering RNA molecules (2015-01-13),

2. 8324370 - Interfering RNA molecules (2012-12-04),

3. 7893245 - Interfering RNA molecules (2011-02-22),

4. 7713943 - Further use of protein kinase N beta (2010-05-11),

5. 7452987 - Interfering RNA molecules (2008-11-18),

Company Overview

Silence Therapeutics Aktiengesellschaft (ag) is a leading biotechnology company focused on the discovery, development, and commercialization of novel therapeutics using RNA interference (RNAi) technology. The company's proprietary platform enables the development of highly specific and efficient RNAi therapeutics for the treatment of various diseases, including cardiovascular diseases, cancer, and rare genetic disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

5 Patents

#180 in D-1000 Berlin

#6,111 in Germany

Berlin, Germany